2028년까지 유럽 피부암 진단 시장 예측 - 유형(흑색종 및 비흑색종) 및 선별 유형(혈액 검사, 피부경 검사, 영상 검사, 림프절 생검 및 피부 생검)별 코로나19 영향 및 지역 분석
No. of Pages: 108 | Report Code: TIPRE00029077 | Category: Life Sciences
No. of Pages: 108 | Report Code: TIPRE00029077 | Category: Life Sciences
2021년 12월 Foundation Medicine, Inc.는 FoundationOneCDx에 대해 FDA 승인을 받았습니다. FoundationOneCDx는 차세대 염기서열분석 기반 체외진단기기입니다. 이는 현재와 미래를 위한 흑색종 치료제로 FDA 승인을 받았습니다. BRAFV600E 돌연변이를 표적으로 하는 BRAF 억제제 단독요법과 BRAFV600E 또는 V600K 돌연변이를 표적으로 하는 BRAF/MEK 억제제 병용요법으로 가능해진다. 이는 종양 전문의의 단순화된 의사결정을 가능하게 하는 중요한 단계로 간주됩니다. 암 진단 회사의 이러한 혁신은 피부암 진단 시장 성장을 주도하고 있습니다.
새로운 기능과 기술을 통해 공급업체는 새로운 고객과 신흥 시장에서 입지를 확장합니다. 이 요인은 상당한 CAGR로 피부암 진단 시장의 성장을 주도하고 있습니다.
피부암 진단 시장은 다음과 같이 분류됩니다. 및 심사 유형. 유형에 따라 시장은 흑색종과 비흑색종으로 분류됩니다. 검사 유형에 따라 시장은 피부 생검, 피부경 검사, 림프절 생검, 영상 검사 및 혈액 검사로 분류됩니다. 국가를 기준으로 시장은 독일, 영국, 프랑스, 스페인, 이탈리아 및 기타 유럽 지역으로 분류됩니다.
SkylineDx BV; AMLo Biosciences Limited; Dermalite LLC; bioMerieux SA; NeraCare GmbH, F. Hoffmann-La Roche Ltd.; 및 Michelson Diagnostics Ltd.는 유럽 피부암 진단 시장의 선두 기업 중 하나입니다.
Strategic insights for Europe Skin Cancer Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 886.6 Million |
| Market Size by 2028 | US$ 1,375.9 Million |
| Global CAGR (2021 - 2028) | 6.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 유형
|
| Regions and Countries Covered | 유럽
|
| Market leaders and key company profiles |
The regional scope of Europe Skin Cancer Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Skin Cancer Diagnostics Market is valued at US$ 886.6 Million in 2021, it is projected to reach US$ 1,375.9 Million by 2028.
As per our report Europe Skin Cancer Diagnostics Market, the market size is valued at US$ 886.6 Million in 2021, projecting it to reach US$ 1,375.9 Million by 2028. This translates to a CAGR of approximately 6.5% during the forecast period.
The Europe Skin Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Skin Cancer Diagnostics Market report:
The Europe Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Skin Cancer Diagnostics Market
